Stay updated on Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The webpage has updated its content to reflect new dates and institutions, replacing previous entries with more current information. Notably, several medical institutions and their specific departments have been removed, indicating a significant shift in the focus of the page.
    Difference
    2%
    Check dated 2025-03-25T13:06:05.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    No Change Detected
  5. Check
    29 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    2%
    Check dated 2025-02-24T16:11:21.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    The page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    2%
    Check dated 2025-02-10T09:09:06.000Z thumbnail image
  7. Check
    51 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.1%
    Check dated 2025-02-03T04:44:51.000Z thumbnail image
  8. Check
    65 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.1%
    Check dated 2025-01-19T12:16:48.000Z thumbnail image
  9. Check
    73 days ago
    Change Detected
    Summary
    The website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in this functionality.
    Difference
    0.3%
    Check dated 2025-01-12T07:20:43.000Z thumbnail image

Stay in the know with updates to Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.